The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Larger Will The Liraglutide And Semaglutide Market Become By 2030 Compared To 2026?
The market for liraglutide and semaglutide has experienced swift expansion over recent years. Projections indicate its expansion from $16.94 billion in 2025 to reach $18.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.5%. This historical growth is linked to factors such as the rising incidence of type 2 diabetes mellitus, inadequacies of conventional antidiabetic treatments, an increase in obesity rates, the proven clinical efficacy of injectable GLP-1 drugs, and a heightened understanding of cardiovascular risk mitigation.
The market size for liraglutide and semaglutide is anticipated to experience substantial growth in the upcoming years. It is projected to reach $28.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This growth during the forecast period can be attributed to several factors, including the expansion of indications for obesity treatment, an increasing demand for convenient dosing options, the rising adoption of oral semaglutide, an enhanced focus on comprehensive metabolic care, and greater healthcare spending allocated to chronic disease management. Significant trends expected during this period encompass the growing adoption of GLP-1 receptor agonists for diabetes care, an expanding use of GLP-1 therapies in obesity management, a heightened preference for once-weekly injectable treatments, the further expansion of oral GLP-1 formulations, and an increase in long-term usage for both glycemic and weight control.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp
What Major Growth Factors Are Impacting The Liraglutide And Semaglutide Market?
An increasing prevalence of diabetic individuals is projected to boost the expansion of the liraglutide and semaglutide markets in the future. Diabetes is a persistent ailment marked by high blood glucose levels, stemming from the body’s resistance to insulin and inadequate insulin synthesis. This growing population of diabetic individuals can be attributed to inactive lifestyles, unhealthy eating patterns, and hereditary factors. Liraglutide and semaglutide play a crucial role in the treatment of diabetic patients, providing effective control over blood glucose and mitigating the likelihood of diabetes-related complications. To illustrate, in June 2024, data from the National Health Service, a government body in the UK, revealed that in 2023, the NHS identified over half a million (549,000) more individuals in England susceptible to type 2 diabetes. This brought the overall count of those diagnosed with non-diabetic hyperglycemia, or pre-diabetes, and registered with a GP, to 3,615,330. This figure indicates a substantial rise when contrasted with 3,065,825 in 2022, demonstrating an increase of nearly 20%. Consequently, the increasing population of diabetic patients serves as a key impetus for the liraglutide and semaglutide markets.
How Are Different Segment Groups Identified Within The Liraglutide And Semaglutide Market?
The liraglutide and semaglutide market covered in this report is segmented –
1) By Type: Pills, Liquid
2) By Administration: Parenteral, Oral
3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations
2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection
Which Trends Are Influencing The Direction Of The Liraglutide And Semaglutide Market?
Leading companies operating within the liraglutide and semaglutide markets are actively developing anti-diabetic biosimilar medications with the aim of improving glucose regulation and mitigating cardiovascular risks for individuals with diabetes. These anti-diabetic biosimilars are economical, nearly identical replicas of original diabetes biologics, designed to offer the same health benefits as the reference drugs. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced a biosimilar of the widely recognized anti-diabetic drug, Liraglutide, for the first time in India. This particular product is a biosimilar of Liraglutide, an anti-diabetic drug intended to enhance glycemic control among adults diagnosed with type 2 diabetes mellitus. This launch results in reduced daily therapy costs, significantly increasing accessibility for more patients nationwide. Offered at approximately INR 100 for a standard 1.2 mg daily dose, it considerably cuts therapy expenses by about 70% and requires a prescription for its purchase.
Who Are The Prominent Players Across The Liraglutide And Semaglutide Market?
Major companies operating in the liraglutide and semaglutide market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals Plc, Viatris Inc., Amneal Pharmaceuticals Inc., Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited
Access The Complete Liraglutide And Semaglutide Market Report:
https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report
Which Region Has The Strongest Presence In The Liraglutide And Semaglutide Market?
North America was the largest region in the liraglutide and semaglutide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Liraglutide And Semaglutide Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp
Browse Through More Reports Similar to the Global Liraglutide And Semaglutide Market 2026, By The Business Research Company
Semaglutides Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/semaglutides-global-market-report
Liraglutide Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report
Antiglaucoma Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model